Search

Crinetics Pharmaceuticals Inc

Suletud

SektorTervishoid

83.72 -0.23

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

83.86

Max

83.97

Põhinäitajad

By Trading Economics

Sissetulek

-5M

-128M

Müük

6.8M

11M

Aktsiakasum

-1.23

Kasumimarginaal

-1,191.029

Töötajad

594

EBITDA

-5M

-127M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

-1.97% downside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

4. aug 2026

Turustatistika

By TradingEconomics

Turukapital

4.5B

8.9B

Eelmine avamishind

83.95

Eelmine sulgemishind

83.72

Uudiste sentiment

By Acuity

50%

50%

145 / 340 Pingereas Healthcare

Crinetics Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. juuli 2026, 23:51 UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit for securities fraud over misleading claims about Fianlimab-Libtayo trial results. Shares are lower in after-hours trading.

21. juuli 2026, 23:51 UTC

News
Social Media

Pegasystems shares declined in after-market trading following second-quarter results that missed analyst expectations for earnings and revenue, amid concerns over future ACV growth.

21. juuli 2026, 23:46 UTC

News

Adobe Inc. shares are declining in after-market trading following Morgan Stanley's downgrade to "underweight" and a reduced price target of $240.

21. juuli 2026, 23:41 UTC

News

Raytheon Technologies secures a $49.7 million Navy contract for weapon system repairs, with shares trading higher in after-market hours.

21. juuli 2026, 23:41 UTC

Social Media
News

Capital One Financial reported adjusted EPS of $5.81 and revenue of $15.85 billion, exceeding expectations, as shares rose in after-market trading.

21. juuli 2026, 23:41 UTC

Macro News
ETF Constituents
News

Vanguard Information Technology ETF is little changed after market hours, despite broader market gains and negative contributions from Apple, Microsoft, and Nvidia.

21. juuli 2026, 23:36 UTC

News
ETF Constituents

The Vanguard Growth ETF is trading roughly flat in after-market hours, reflecting minor fluctuations among its holdings, including declines from Apple, Microsoft, and Nvidia.

21. juuli 2026, 23:36 UTC

Social Media
News

Micron Technology rose in after-market hours, supported by a semiconductor rally and a Bank of America upgrade to "buy" on strong AI demand.

21. juuli 2026, 23:36 UTC

News

MongoDB shares traded higher after director Dwight Merriman sold 16,000 shares for $5.2 million under a pre-scheduled plan, retaining $496.55 million in holdings.

21. juuli 2026, 23:32 UTC

News

United Community Banks Inc. shares rise in after-market trading after an upgrade to Buy, bolstered by Q2 2026 net interest income of $270.7 million.

21. juuli 2026, 23:26 UTC

Correlated Moves
News

JPMorgan Chase & Co shares showed little change in after-market hours amid broader market movements. CEO Jamie Dimon raised concerns over geopolitical tensions and inflation.

21. juuli 2026, 23:26 UTC

Social Media
Correlated Moves
News

Coinbase Global shares rose in after-market trading amid reports of a regulatory agreement that may benefit digital assets, with Bitcoin approaching $67,000.

21. juuli 2026, 23:26 UTC

News

Lucid Group Inc. faces a class action lawsuit over alleged supplier quality issues, contributing to a decline in after-market trading. Shares earlier stabilized after a session low.

21. juuli 2026, 23:26 UTC

News

Intuit Inc. shares are lower in after-market trading following a class action lawsuit alleging misleading statements about TurboTax revenue growth and competitive advantages.

21. juuli 2026, 23:16 UTC

News

Sprinklr Inc reported first-quarter revenues of $219.5 million, exceeding expectations, but shares are lower in after-market hours amid sector concerns and mixed AI sentiments.

21. juuli 2026, 23:16 UTC

News

Nasdaq shares rise in after-market hours following the dismissal of all claims in the Miami International litigation, positively impacting investor sentiment.

21. juuli 2026, 23:16 UTC

News

Iridium Communications Inc. shares are higher in after-hours trading, reflecting positive market sentiment amid significant gains in technology and semiconductor stocks in Asia.

21. juuli 2026, 23:16 UTC

News

Intel faces valuation scrutiny as modest growth expectations contrast with sector leaders benefiting from AI demand. Shares were roughly flat in after-market hours.

21. juuli 2026, 23:11 UTC

News

Toast Inc shares are trading higher in after-market hours following the announcement of its second quarter 2026 financial results release on August 4.

21. juuli 2026, 23:11 UTC

News

Pfizer Inc. options trading showed light volume, with calls outpacing puts and a put/call ratio of 0.56. Shares were little changed in after-market hours.

21. juuli 2026, 23:06 UTC

News

General Motors plans a new generation of gasoline-powered Cadillac models, shifting from an all-electric strategy. Shares are higher in after-market trading.

21. juuli 2026, 23:02 UTC

News

Park Aerospace shares lower in after-market hours following the unexpected death of Vice President Daniel McNamara, impacting investor sentiment and contributing to the decline.

21. juuli 2026, 23:02 UTC

Event
News

Weatherford International shares advanced in after-market trading following second-quarter results, with revenues of $1.11 billion exceeding expectations despite a decline.

21. juuli 2026, 23:02 UTC

News

Jefferies raised its price target on Genuine Parts Co to $130.00, contributing to after-market gains following a dip earlier in the session.

21. juuli 2026, 23:02 UTC

Event
News
Social Media

AAR Corp shares are lower in after-market trading following mixed fourth-quarter results and cautious guidance, despite exceeding sales and EPS expectations.

21. juuli 2026, 23:02 UTC

News

ServiceNow Inc. shares declined in after-market hours amid concerns about generative AI's impact on the enterprise software sector, according to Morgan Stanley.

21. juuli 2026, 23:01 UTC

News
Social Media

Citigroup Inc declared a quarterly dividend of $0.67 per share, though shares are trading lower after-market amid ongoing market weakness.

21. juuli 2026, 23:01 UTC

News

Norfolk Southern announced a quarterly dividend of $1.35 per share, contributing to shares trading higher in after-market hours following three lower sessions.

21. juuli 2026, 23:01 UTC

News

DigitalOcean shares rise in after-market hours after Baird analyst initiates coverage with an Outperform rating. The stock closed at $119.09 in the prior session.

21. juuli 2026, 23:01 UTC

News
Social Media

Chubb Ltd reported second-quarter net income of $2.85 billion, down from $2.97 billion a year earlier, contributing to lower after-market trading.

Võrdlus sarnastega

Hinnamuutus

Crinetics Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

-1.97% langus

12 kuu keskmine prognoos

Keskmine 82.22 USD  -1.97%

Kõrge 95 USD

Madal 55 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Crinetics Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

14 ratings

3

Osta

11

Hoia

0

Müü

Sentiment

By Acuity

145 / 340 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat